Evidence map›Paper›PMID 37933735›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2024

Post-stroke brain can be protected by modulating the lncRNA FosDT.

Suresh L Mehta, Bharath Chelluboina, Kahlilia C Morris-Blanco, Saivenkateshkomal Bathula, Soomin Jeong, Vijay Arruri, Charles K Davis, Raghu Vemuganti

Open access · greenAbstract read
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. DPSCs-Exos promote OPCs differentiation and white matter repair via Myl9-mediated PRMT5 nucleation after ischemic stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Loss of Epitranscriptomic Modification NTranslational stroke research · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Suresh L MehtaDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.
Bharath ChelluboinaDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.ORCID 0000-0001-8834-6484
Kahlilia C Morris-BlancoDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.
Saivenkateshkomal BathulaDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.
Soomin JeongDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.
Vijay ArruriDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.
Charles K DavisDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.ORCID 0000-0002-6342-6565
Raghu VemugantiDepartment of Neurological Surgery University of Wisconsin, Madison, WI, USA.
University of Wisconsin–Madison · US

Funding

Therapeutic Targeting of an lncRNA in Experimental Stroke Using STAIR CriteriaR01NS099531 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI VEMUGANTI, RAGHU · 2017 to 2021
$2.0M
BLRD Research Career Scientist Award ApplicationIK6BX005690 · VA · WM S. MIDDLETON MEMORIAL VETERANS HOSP · PI VEMUGANTI, RAGHU · 2021 to 2025
–
BLRD VA IK6 BX005690NINDS NIH HHS R01 NS099531
6 · The paper itself

Abstract

We previously showed that knockdown or deletion of Fos downstream transcript (FosDT; a stroke-induced brain-specific long noncoding RNA) is neuroprotective. We presently tested the therapeutic potential of FosDT siRNA in rodents subjected to transient middle cerebral artery occlusion (MCAO) using the Stroke Treatment Academic Industry Roundtable criteria, including sex, age, species, and comorbidity. FosDT siRNA (IV) given at 30 min of reperfusion significantly improved motor function recovery (rotarod test, beam walk test, and adhesive removal test) and reduced infarct size in adult and aged spontaneously hypertensive rats of both sexes. FosDT siRNA administered in a delayed fashion (3.5 h of reperfusion following 1 h transient MCAO) also significantly improved motor function recovery and decreased infarct volume. Furthermore, FosDT siRNA enhanced post-stroke functional recovery in normal and diabetic mice. Mechanistically, FosDT triggered post-ischemic neuronal damage via the transcription factor REST as REST siRNA mitigated the enhanced functional outcome in FosDT

Indexed as

Brain IschemiaDiabetes Mellitus, ExperimentalNeuroprotective AgentsRNA, Long NoncodingStrokeAnimalsBrainFemaleInfarction, Middle Cerebral ArteryMaleMiceNF-kappa BRatsRats, Inbred SHRRNA, Small InterferingNeuroprotective AgentsNF-kappa BRNA, Long NoncodingRNA, Small InterferingCerebral ischemiacomorbidityneuroprotectionnoncoding RNAtherapytranscriptional regulation

Identifiers

PMID37933735
PMCPMC10993881
OpenAlexW4388463654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.